Aspire files patent application for clopidogrel sublingual powder formulation

1 week ago 4

TipRanks

Wed, January 28, 2026 astatine 7:26 AM CST 1 min read

Aspire Biopharma (ASBP) announced the filing of a caller provisional patent exertion with the United States Patent and Trademark Office. The application, titled “A Sublingual Powder Formulation of Clopidogrel and Methods of Use Thereof,” covers the first-ever sublingual formulation of clopidogrel, the progressive pharmaceutical constituent successful the wide prescribed humor thinner Plavix. This improvement represents a bid of sublingual-based therapeutic alternatives the Company intends to commercialize via the FDA’s 505(b)(2) regulatory pathway. Aspire’s strategical pipeline focuses connected reformulating approved generic therapeutics to code unmet needs wherever nary sublingual alternatives presently exist, frankincense bringing the benefits of reducing oregon eliminating gastric irritation to products with these known broadside effects.

Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions
Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See today’s best-performing stocks connected TipRanks >>

Read More connected ASBP:

Disclaimer & DisclosureReport an Issue

Aspire Biopharma takes transportation of 2M units of BUZZ BOMB
Aspire Biopharma launches marque redesign for BUZZ BOMB
Aspire Biopharma files patent exertion for sublingual alprazolam formulation
Aspire Biopharma Holdings Inc trading halted, quality pending
Aspire Biopharma Adopts Equity Plan Limits and Award Agreements

Read Entire Article